BBA
NVIV

Baker Bros. Advisors’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Baker Bros. Advisors’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-18
Closed -$255K – 125
2017
Q4 		$255K Sell
18
-3
-14% -$69.4K ﹤0.01% 120
2017
Q3 		$580K Hold
21
– – ﹤0.01% 114
2017
Q2 		$1.08M Hold
21
– – 0.01% 99
2017
Q1 		$1.62M Hold
21
– – 0.01% 92
2016
Q4 		$1.68M Hold
21
– – 0.02% 96
2016
Q3 		$2.72M Hold
21
– – 0.02% 85
2016
Q2 		$2.31M Hold
21
– – 0.02% 94
2016
Q1 		$2.79M Buy
+21
New +$2.25M 0.03% 90

Other funds holding NVIV

ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Baker Bros. Advisors's NVIV Position: Q1 2018 in Review

Baker Bros. Advisors sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2018, closing a stake of 18 shares — an estimated $255K sold.

Baker Bros. Advisors first reported a position in NVIV in Q1 2016 and held it in 8 quarters. The position peaked at $2.79M in Q1 2016. 25 funds tracked by Wall St. Rank hold NVIV as of Q1 2018.

  • Baker Bros. Advisors reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2018 after selling out during the quarter.
  • Baker Bros. Advisors sold 18 InVivo Therapeutics Holdings Corp shares in Q1 2018, an estimated $255K.
  • Baker Bros. Advisors first reported a position in InVivo Therapeutics Holdings Corp in Q1 2016 and held it in 8 quarters.
  • Baker Bros. Advisors's InVivo Therapeutics Holdings Corp position peaked at $2.79M in Q1 2016.
  • 25 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2018.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.